1Choi MJ,Eustsce JA,Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular disease[J]. Kidney Int, 2002, 61 (3): 1098-1114. 被引量：1
2Tam LS, Li KE, Wong CK, et al. Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus[J]. Lupus, 2004,13 (8): 601-604. 被引量：1
6Kirwan JR.The effect of glucoeurticoid on joint destruction in rheumatoid arthritis.The arthritis and rheumatism council low-dose glucocorticoid study group[J]. N Engl J Med. 1995,333(3): 142 - 146 被引量：1
7Van Everdingen AA, Jacobs JWG, Van Reesema DR, et al.Low-dose prednisone therapy for patient with early active rheumatoid arthritis: clinical efficacy, disease modifying properties, and side effect [ J ]. Ann Intern Med,2002,136(1) : 1 - 12 被引量：1
8Pincus T, Sokka T, Stein CM, et al.Are long-term very low doses prednisone for patients with rheumatoid arthritis as helpful as high doses are harmful? [J].Ann Inem Med,2002,136(1) :76-78 被引量：1
9Austin HA. Therapy of lupus nephritis: controlled trial of prednisone and cytoxic drugs. New Engl J Med, 1986, 314:614-619. 被引量：1
10Vasquez S, Kavanaugh AF, Schneider NR, et al. Acute nonlymphocytic leukemia after treatment of systemic lupus erythematosus with immunosuppressive agents. J Rheumatol,1992, 19: 1625. 被引量：1
9Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of lefluno- midecompared with placebo and sulphasalazine in active rheumatoid arthritis : a double-blind, randomised, muhicentre trial. European Le- flunomide StudyGroup [ J]. Lancet, 1999,353 (9149) :259 - 266. 被引量：1
10Mieeli-Riehard C, Dougados M. Leflunomide for the treatment of rheumatoid arthritis [ J ]. Expert Opin Pharmaeother, 2003,4 ( 6 ) : 987 - 997. 被引量：1
